Infigratinib 25mg Capsules

Infigratinib 25mg Capsules are a targeted cancer therapy known as a kinase inhibitor, specifically designed to combat advanced cholangiocarcinoma (bile duct cancer). The medication works by selectively blocking the activity of fibroblast growth factor receptors (FGFR), a family of proteins that, when mutated or overactive, can drive the uncontrolled division and survival of cancer cells. By inhibiting these receptors, Infigratinib 25mg Capsules disrupt the signaling pathways essential for tumor growth.

This potent mechanism makes Infigratinib 25mg Capsules a critical option for patients whose cancer harbors specific genetic alterations, known as FGFR2 fusions or rearrangements. By attacking the cancer cells directly at the molecular level, this oral medication aims to slow disease progression and shrink tumors. It represents a personalized medicine approach, offering hope where traditional chemotherapy may have limited efficacy.

Clinicians prescribe Infigratinib 25mg Capsules as a convenient, once-daily treatment that can be taken at home. This powerful intervention is particularly significant for patients with previously treated, unresectable, or metastatic bile duct cancer, providing a valuable therapeutic tool in the fight against this aggressive disease.

Indications / Uses of Infigratinib 25mg Capsules

Infigratinib 25mg Capsules are commonly prescribed for:

• Cholangiocarcinoma with FGFR2 Fusions: The primary indication is for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 fusion or other rearrangement as detected by an FDA-approved test.
• Targeted Therapy for Genetic Mutations: It is specifically used for patients whose tumors have been genetically profiled and confirmed to carry susceptible FGFR2 alterations, making it a precision medicine treatment.
• Advanced Disease Management: This medication serves as a vital second-line or subsequent therapy for patients whose cancer has progressed despite prior systemic treatments, offering a new line of defense.
• Tumor Growth Inhibition: By blocking the FGFR signaling pathway, Infigratinib 25mg Capsules help to halt the proliferation of cancer cells and induce cell death in tumors driven by these specific genetic drivers.

Key Features

• Selective FGFR Kinase Inhibitor: Infigratinib 25mg Capsules are engineered to specifically bind to and inhibit FGFR1, FGFR2, and FGFR3, with a high potency for FGFR2, directly targeting the driver of the malignancy.
• Oral Administration: The medication is available as capsules, typically taken once daily on an empty stomach. This oral route offers convenience and ease of use compared to intravenous chemotherapy regimens.
• Precision Medicine Approach: Efficacy is linked to specific biomarkers (FGFR2 fusions/rearrangements), ensuring that the treatment is directed at patients most likely to benefit based on their tumor’s genetic makeup.
• manageable Dosing Schedule: The standard dosing regimen often involves a cycle (e.g., 21 days on, 7 days off), allowing for a balance between therapeutic efficacy and recovery from potential side effects.
• Systemic Efficacy: As a systemic therapy, it circulates throughout the body to reach metastatic sites, addressing cancer that has spread beyond the primary bile duct location.

Storage for Infigratinib 25mg Capsules

Store Infigratinib 25mg Capsules at controlled room temperature, typically between 68°F to 77°F (20°C to 25°C). Excursions are permitted between 59°F and 86°F (15°C to 30°C). Keep the medication in its original container to protect it from moisture and humidity. Do not remove any desiccant packets included in the bottle. Store the bottle in a dry place, away from direct sunlight and excess heat, and ensure it is kept out of the reach of children and pets.

Important Note on Infigratinib 25mg Capsules

Monitoring and Side Effects: Treatment with Infigratinib 25mg Capsules requires regular monitoring by a healthcare provider. Common side effects can include hyperphosphatemia (high phosphate levels in the blood), nail toxicity, stomatitis (mouth sores), dry eyes, and fatigue. Patients may need to take phosphate binders or adjust their diet to manage phosphate levels.

Ocular Toxicity: This medication can cause serious eye problems, such as retinal pigment epithelial detachment (RPED) and dry eyes. Comprehensive eye exams are recommended before starting treatment and regularly during therapy. Patients should report any changes in vision or eye discomfort immediately.

Dosing Instructions: Take the capsules on an empty stomach, at least 1 hour before or 2 hours after a meal. Swallow the capsules whole with a glass of water; do not crush, chew, or dissolve them. If a dose is missed by more than 4 hours, skip it and take the next dose at the scheduled time.

Pregnancy and Breastfeeding: Infigratinib can cause fetal harm. Females of reproductive potential and males with female partners should use effective contraception during treatment and for a specified period after the final dose. Breastfeeding is not recommended during treatment.